
==== Front
J Biol Chem
J Biol Chem
The Journal of Biological Chemistry
0021-9258
1083-351X
American Society for Biochemistry and Molecular Biology

S0021-9258(24)02183-5
10.1016/j.jbc.2024.107682
107682
JBC Reviews
The impact of aging on cardiac repair and regeneration
Anwar Iqra
Wang Xinghua
Pratt Richard E.
Dzau Victor J.
Hodgkinson Conrad P. conrad.hodgkinson@duke.edu
∗
Mandel Center for Heart and Vascular Research, Duke Cardiovascular Research Center, Duke University Medical Center, Durham, North Carolina, USA
∗ For correspondence: Conrad P. Hodgkinson conrad.hodgkinson@duke.edu
17 8 2024
9 2024
17 8 2024
300 9 10768229 4 2024
10 7 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
In contrast to neonates and lower organisms, the adult mammalian heart lacks any capacity to regenerate following injury. The vast majority of our understanding of cardiac regeneration is based on research in young animals. Research in aged individuals is rare. This is unfortunate as aging induces many changes in the heart. The first part of this review covers the main technologies being pursued in the cardiac regeneration field and how they are impacted by the aging processes. The second part of the review covers the significant amount of aging-related research that could be used to aid cardiac regeneration. Finally, a perspective is provided to suggest how cardiac regenerative technologies can be improved by addressing aging-related effects.

Keywords

aging
regeneration
heart
cardiac
fibroblast
cardiomyocyte
mitochondria
Abbreviations

CDK cyclin-dependent kinase

ERK extracellular signal-regulated kinase

iPSC inducible pluripotent stem cell

OSKM Oct4, Sox2, Klf4, and c-Myc

ROS reactive oxygen species

SASP senescence-associated secretory phenotype

SS Szeto-Schiller

TGF transforming growth factor

TLR toll-like receptor

VEGF vascular endothelial growth factor

Reviewed by members of the JBC Editorial Board. Edited by Roger Colbran
==== Body
pmcThe inability of the adult human heart to repair itself makes it particularly vulnerable to the effects of aging. Cardiac aging results in the permanent loss of cardiac muscle cells, mitochondrial dysfunction, and development of fibrosis. These changes in the heart are progressive; they negatively impact cardiac function and are fertile ground for heart failure. In addition, aging also weakens the response of the heart to cardiac injury. Thus, in the aged, cardiac injury is often associated with poorer outcomes. The field of cardiac regeneration seeks to reverse fibrosis, induce vascularization, and replenish the cardiac muscle cell population. These would be useful to reverse the effects of aging. However, seeing as most of this research has been conducted in young animals, the relevance to older animals is often unclear. This review discusses attempts to regenerate the damaged heart as well as the impact of aging thereon. The review concludes with a discussion of how research into the mechanisms of cardiac regeneration can be repositioned to reverse the deleterious effects of cardiac aging.

Aging changes the heart’s response to cardiac injury

As the heart ages, the capacity of the organ to respond to increased workload decreases. The stress this entails promotes diastolic dysfunction, arrhythmias, and heart failure (1). These changes to the normal function of the heart ensure that young and aged adults respond differently to cardiac injury.

In young adults, cardiac injury initially induces an inflammatory response, whereby neutrophils, M1 macrophages, T cells, and B-cells invade the injury area to remove dead cells and initiate the reparative phase. The reparative phase is associated with a shift in immune cell populations which actively resolve inflammation and induce fibroblasts to secrete fibrous tissue proteins. The latter results in a stable scar (2). In contrast, the inflammatory response in older hearts following injury is muted, resulting in delayed clearance of dead cells. Moreover, fibroblast responses to fibrotic cues are markedly weaker. Fibrous protein production is dampened, leading to weaker and less stable scars. Weaker scars affect cardiac function by increasing systolic dysfunction and dilative remodeling. Dampened immune and fibroblast responses in aged individuals lower the capacity to respond to stressors (2).

The effect of aging on molecular mechanisms for cardiac regeneration

Cardiac regeneration research has predominantly focused on angiogenesis, reducing fibrosis, and restoring the cardiac muscle cell (cardiomyocytes) population (Fig. 1) (3). In this section, the molecular mechanisms of cardiac regeneration are discussed and how they are affected by aging.Figure 1 Mechanisms in mammalian cardiac regeneration.A, VEGF therapies for revascularization are undergoing clinical evaluation for safety. The molecular mechanism involves the indicated kinases. B, triggers for fibrosis include ROS, proinflammatory cytokines such as IL6, and growth factors including TGFβ. TGFβ inhibitors are showing promise in preclinical animal models. C, cellular reprogramming refers to the process, whereby scar fibroblasts are converted in situ into new cardiomyocytes. Ostensibly, reprogramming factors work by modulating the activity/function of activators and inhibitors. Inhibitor pathways are mainly epigenetic, such as H3K27me3 and H2AK11ub. These epigenetic motifs are regulated by the indicated proteins. These proteins are direct targets for reprogramming factors. Less is known about TGFβ inhibition. Various activator pathways have been reported including immunity (Rig1, TLR3, and IFNβ), autophagy (Atg5), and growth factor signaling (Akt). D, cardiomyocyte proliferation is nonexistent in the adult mammalian heart. Proliferation can be induced through certain growth factors or the overexpression of various CDKs and their cognate cyclins. Another approach is targeting cardiomyocyte cell cycle inhibitors. Manipulation of various kinase signaling pathways has also proven fruitful. Interestingly, these kinase pathways appear to augment each other’s activity. CDK, cyclin-dependent kinase; ROS, reactive oxygen species; TLR, toll-like receptor; VEGF, vascular endothelial growth factor.

Angiogenesis

Blood vessels play a crucial role in delivering oxygen and metabolites to tissues while removing waste products. The formation of new blood vessels is vital for tissue regeneration. Cardiac damage provides a trigger for revascularization through arteriogenesis; whereby, existing arterioles are remodeled into larger blood vessels in an attempt to restore blood flow (4). Unfortunately, native myocardial arteriogenesis is generally insufficient. Researchers have sought ways to enhance the process by elucidating and targeting the mechanisms of vasculogenesis and angiogenesis (4). Despite a plethora of proteins and noncoding RNAs being known to regulate these processes, clinical applications have so far focused on vascular endothelial growth factor (VEGF). VEGF promotes angiogenesis by stimulating the kinases PKC, PI3K, Akt, and MAPK (5, 6, 7) (Fig. 1A). Various VEGF variants exist (e.g., VEGF-A and VEGF-B) and one of the most advanced therapeutics for revascularization is an mRNA that produces VEGF-A (8, 9, 10, 11). Unfortunately, clinical trials have not yielded particularly encouraging results.

Compounding these issues, angiogenesis is likely to be more difficult in aged individuals. Vascular progenitors decrease significantly in number with age (12). Moreover, studies in rodents show that aging impairs angiogenesis in response to injury by inhibiting vascular sprouting and branching. This leads to a lower number of capillaries and a poorly formed vascular network. Impaired angiogenesis in aged individuals is likely due to changes in the extracellular matrix. The extracellular matrix binds to blood vessel precursor cells to direct vascular sprouting and induce capillary formation. As individuals age, several extracellular matrix proteins change their form. Collagen fibrils become longer and thicker; elastin structure becomes disordered; and the globular structure of fibronectin is changed. Moreover, other extracellular matrix proteins such as decorin and laminin undergo changes in expression. The net result is a stiffer extracellular matrix which impedes angiogenesis (13). The trigger for these changes in the extracellular matrix is age-induced increases in the numbers of senescent cells (13).

Regulation of fibrosis

Fibrosis is the development of scars due to excess deposition of extracellular matrix components in response to injury. In the absence of meaningful cardiac muscle regeneration, fibrosis maintains the integrity of the heart after injury. Myofibroblasts are key effectors; however, notable roles are also played by immune cells such as macrophages, mast cells, and lymphocytes (Fig. 1B).

Research into the mechanisms of fibrosis comes mostly from younger animals. Secreted molecules that induce fibrosis include proinflammatory cytokines (IL-1α, IL-1β, IL-6, TNF-α, and C-X-C motif ligands-1, 2, 5, and 8), mast cell-derived proteases, endothelin-1, and growth factors such as platelet derived growth hormone and transforming growth factor (TGF)-β (14, 15, 16). In addition, mechanical stressors promote fibrosis via integrins and mechanosensitive ion channels. Once stimulated, integrins and mechanosensitive ion channels induce fibroblasts to secrete collagens via the activation of a number of kinases including focal adhesion kinase, Rho-associated protein kinase, and mitogen-activated protein kinase (17). Due to its central role in mediating the differentiation of cardiac fibroblasts to myofibroblasts, TGF-β has been the main focus for the development of antifibrotic therapies (Fig. 1B) (18, 19). Whether such a strategy is viable in older individuals is less clear. In young individuals, cardiac fibroblasts respond robustly to TGF-β and the fibrotic scar that they form is effective in maintaining heart integrity. With aging, the cardiac fibroblast responses to TGF-β diminish. Reduced responses to TGF-β results in scars that are inadequate and the stresses that this imposes on the heart can lead to organ failure (20).

Aging is also associated with interstitial fibrosis, a broad, diffuse scarring that affects cardiac function. The extracellular matrix within the heart is maintained by cardiac fibroblasts. These cells secrete various matrix proteins as well as matrix-modifying enzymes. In young individuals, cardiac fibroblasts are effective in maintaining the extracellular matrix. In contrast, in aged individuals, cardiac fibroblasts no longer respond correctly to external stimuli. In their dysfunctional state, cardiac fibroblasts are unable to effectively manage collagen. Collagen fibers build up between cells and results in interstitial fibrosis. Interstitial fibrosis stiffens the heart walls, leading to systolic dysfunction and heart failure. Heart failure as a consequence of interstitial fibrosis is very common, and due to the aging population, the incidence is projected to double within 40 years. To date, there are no effective treatments. From a mechanistic viewpoint, aging associated increases in extracellular signal-regulated kinase (ERK)1/2 signaling have linked to interstitial fibrosis (20). While the exact reason for increased ERK1/2 signaling is unclear, increases in circulatory levels of growth factors such as insulin as well as age-related decreases in the expression of phosphatases such as DUSP1 and protein phosphatase 2A may play a role (20). Similarly, increased levels of reactive oxygen species(ROS) are a known trigger for interstitial fibrosis through the activation of ERK1/2 (21, 22, 23). Pertinent to the scope of this review, mice lacking the ROS scavenger superoxide dismutase quickly exhibit rapid onset of cardiac fibrosis and succumb within a short span of life, whereas overexpression of this enzyme prevents cardiac fibrosis in aged mice (24, 25).

Cardiomyocyte generation via direct reprogramming

Injury and aging results in the permanent loss of cardiac muscle cells (cardiomyocytes). One option to regenerate the cardiomyocyte population is through direct cellular reprogramming. Direct cellular reprogramming involves the conversion of one somatic cell type into another without the need for a stem cell intermediate. In cardiac regeneration research, cardiomyocytes are generated from the direct reprogramming of fibroblasts. This has been achieved via pharmacological inhibitors, transcription factors and miRNAs (26, 27, 28, 29). Initially, the process was generally inefficient due to a lack of understanding of the mechanisms involved. By its very nature, reprogramming has to overcome potent barriers that safeguard cell identity. Thus, research in the field has concentrated on identifying these barriers. One such barrier is epigenetic modifications. Cardiomyocyte genes are silent in fibroblasts by virtue of inhibitory histone modifications such as H3K27me3 (30, 31) and H2AK119ub (32). These inhibitory histone modifications have to be actively maintained and this is achieved by Bmi1, Cbx1, PurB, and Sp3 (32, 33). The expression of these proteins is reduced by reprogramming factors, resulting in replacement of inhibitory histone modifications for those that promote transcription such as H3K4me3 (30, 31) (Fig. 1C). On their own, reduced expression of Bmi1, Cbx1, PurB, and Sp3 has little effect on fibroblast gene expression. This is a problem because continued expression of fibroblast genes would prevent the reprogramming cells from fully becoming cardiomyocytes. Fibroblast gene suppression can be achieved by inhibiting the TGF-β (34, 35, 36, 37) and Notch (38) signaling pathways. Both TGF-β and Notch are profibrotic, suggesting that profibrotic pathways represent a barrier to reprogramming. However, Akt1 activation, which is profibrotic, has been reported to be necessary for reprogramming (39) (Fig. 1C).

Another potential barrier to reprogramming is provided by autophagy. Autophagy is a crucial cellular process responsible for breaking down cytoplasmic proteins and organelles to recycle their components. Pharmacological activation of the autophagy mediator Atg5 was found to improve reprogramming efficacy (40). Surprisingly, the same was found when the authors depleted another autophagy mediator, Becn1. The authors concluded that Becn1 knockdown induced Wnt signaling and suggested that Becn1 was operating independently of its effects on autophagy (40). Due to the complex picture provided, further studies are warranted.

An additional barrier is the requirement to activate innate immunity pathways. It was initially observed that the method by which reprogramming factors were delivered into cells strongly affected outcomes; only those modes of delivery that induced innate immunity were found to be successful. Further studies into the mechanisms by which innate immunity regulated reprogramming identified important roles for the RNA-sensing receptors toll-like receptor (TLR) 3 and Rig1. TLR3 and Rig1 promote reprogramming through epigenetic pathways as well by activating transcription factors which stimulate cardiomyocyte gene expression (41, 42, 43) (Fig. 1C).

Studies in fibroblast to cardiomyocyte reprogramming have been conducted solely in neonatal and young animals. Thus, it is open to conjecture as to how the aforementioned barriers are affected by aging. Moreover, aging itself may also impose additional barriers. The latter appears quite likely as targeting the oxygen sensor Epas1 was found to improve fibroblast to cardiomyocyte reprogramming efficacy in older mice while having no effect in neonatal animals (44). Another potential issue is the extent to which reprogrammed cells retain aging-related features of the original cell type. Indeed, this has been observed in the direct reprogramming of fibroblasts into neurons (45). Carrying over aging-related fibroblast dysfunction into cardiomyocytes could potentially impair cardiac function.

Cardiomyocyte proliferation

Adult cardiomyocytes proliferate weakly, if at all. Thus, cardiac regeneration could be achieved if these adult cardiomyocytes were coaxed to proliferate. The focus on adult cardiomyocyte proliferation has been considerable. Demonstrating true cardiomyocyte division has proven to be quite difficult as the cells will often express various cell cycle proteins, including those involved in cytokinesis, without actively dividing. Moreover, it is important not to just restore numbers but also functionality. Cardiomyocytes derived from inducible pluripotent stem cells (iPSCs) could potentially generate sufficient quantities for meaningful regeneration. However, to date, iPSC-derived cardiomyocytes are functionally immature.

Many growth factors have been reported to induce cardiomyocyte division in young animals. However, the majority only increases cardiomyocyte cell size and only a few appear to lead to cytokinesis. Growth factors associated with cytokinesis, and thus effective proliferation, include neuregulin-1, insulin-like growth factor-1, fibroblast growth factor-1, and TNF-related weak inducer of apoptosis (46, 47, 48, 49, 50) (Fig. 1D).

Growth factors mediate their effects on proliferation through signaling pathways. Signaling pathways identified as being important for cardiomyocyte division include PI3K-Akt, Wnt/β-catenin, and Hippo-YAP (51, 52, 53, 54). These pathways reinforce each other in a positive feedback loop, beginning with PI3K-Akt phosphorylation and inactivation of GSK3β. In the absence of GSK3β activity, β-catenin is stabilized and accumulates in the nucleus (55). Nuclear β-catenin is a necessary cofactor for YAP-mediated transcription (56). One of the targets of the YAP transcription factor is Pi3kcb (54). To close the loop, Pi3kcb activates PI3K-Akt (54) (Fig. 1D).

The PI3K-Akt, Wnt/β-catenin, and Hippo–YAP pathways promote division by modulating the expression of proteins involved in the cell cycle. The events of the cell cycle are governed by cyclins and their binding partners, the cyclin-dependent kinases (CDKs). Cyclins and CDKs mediating the effect of the aforementioned signaling pathways include cyclin-A2, cyclin-B1, cyclin-D1, cyclin-D2, CDK1, and CDK4 (57, 58, 59, 60) (Fig. 1D). PI3K-Akt, Wnt/β-catenin, and Hippo-YAP signaling also affect the expression of cell cycle inhibitors. CDK inhibitors block cell cycle progression by reducing CDK-cyclin activity. Adult cardiomyocytes express the CDK inhibitors p21, p27, and p57 (61). Under conditions that stimulate PI3K-Akt, p27 expression is reduced and cardiomyocytes undergo G2/M phase progression (62).

Manipulating these mechanisms is effective in restarting cardiomyocyte proliferation in young animals. Research suggests reduced efficacy in aged individuals. The capacity of cardiomyocytes to proliferate decreases with age (63, 64, 65, 66); implying that aging promotes proliferation resistance. The impact of proliferation resistance is further compounded by findings that suggest that activation of PI3K–Akt and Wnt/β–catenin pathways are deleterious in aged individuals. In aged mice, inhibition of PI3K-Akt signaling reduced age-related declines in cardiac function. The antiaging effects of reduced PI3K-Akt signaling activity were related to enhanced oxidative phosphorylation and increased autophagic flux (67). The authors of this study also noted enhanced PI3K-Akt signaling activity in failing human hearts (67). Similarly, aging is also associated with increased β-catenin levels (68) and this may play a role in pathophysiological remodeling (69). Human data with respect to aging and the activity of Hippo–YAP pathway is lacking. However, results from related systems are promising. To explain the promising data, a primer on Hippo-YAP signaling is needed. When the Hippo–YAP pathway is active, YAP is restrained in the cytoplasm. When the pathway is in the inactive state, YAP moves to the nucleus and activates genes. Interventions designed to turn the Hippo–YAP pathway off have been shown to induce cardiomyocyte proliferation in mice up to 8 months of age, equivalent to early middle age in humans (52). Moreover, heart failure in humans has been shown to activate Hippo-YAP (70).

What can aging research teach us about cardiac regeneration?

As described in the previous section, the cardiac regenerative field has identified many mechanisms that effectively regenerate the hearts of young, but not aged, individuals. Interventions based on these mechanisms have not arrived in the clinic. This may be because they have not fully taken into account the effects of aging. In the previous section, we discussed how the main mechanisms are affected by aging. However, there is plenty of additional aging research that could be used to help cardiac regeneration. That research is the focus of this section.

Reactive oxygen species

Cellular homeostasis relies on the oxidation-reduction (redox) system. Under physiologic conditions, the redox system maintains a balance between the generation and removal of ROS. A short duration of increased ROS may limit injury. However, if increased ROS levels are prolonged then significant damage occurs to cells. The importance of ROS in cardiac aging has been shown through the overexpression of antioxidant proteins. Expression of the antioxidant enzyme catalase in mitochondria improves lifespan in mice and reduces cardiac aging phenotypes such as hypertrophy and diastolic dysfunction (71). Aging leads to changes in the expression of enzymes involved in maintaining the equilibrium of the redox system, tipping the balance toward increased ROS levels. Exogenous sources of ROS include nitric oxide oxidase and NADPH oxidases. However, the dominant source of ROS in aging is the mitochondria (72).

Mitochondria generate ATP through the electron transport chain. The electron chain is comprised of four enzymatic complexes numbered I, II, III, and IV. Complexes I and III are the main sources of ROS. Aging induces a defect in the ubiquinol binding site (Q(O)) within complex III, the result being increased ROS production. Increased ROS generation from complex III disrupts calcium handling within the endoplasmic reticulum, inducing stress within the organelle. A stressed endoplasmic reticulum impairs complex I activity, which also increases ROS generation. Increased ROS generation weakens mitochondria. Mitochondrial integrity is maintained in part by the phospholipid cardiolipin. In response to increased ROS, cardiolipin levels fall, resulting in damage to the inner mitochondrial membrane. Similarly, increased ROS also promotes damage to the mitochondrial genome (Fig. 2) (72).Figure 2 Molecular pathways in cardiac aging. Aging is associated with reduced cardiac function. As the heart ages, mitochondria become dysfunctional and cells become senescent. The net result is an increase in ROS levels and the production of proinflammatory proteins respectively. ROS and proinflammatory proteins set up a positive feedback loop which increases cellular senescence and impairs regenerative capacity. ROS, reactive oxygen species.

Increased ROS production, structural changes, and genetic damage are the hallmarks of a dysfunctional mitochondria. The process by which dysfunctional mitochondria are removed is called mitochondrial autophagy (mitophagy). In young individuals, mitophagy is effective and dysfunctional mitochondria are rapidly cleared before excessive ROS production can do significant damage. Mitophagy becomes less effective in the aging heart, leading to ever increasing numbers of dysfunctional mitochondria and a vicious circle of ever increasing ROS generation (Fig. 2) (73, 74).

Increased ROS not only damages mitochondria but it also promotes interstitial fibrosis, hypertrophy, senescence, inflammation, and contractile dysfunction.

ROS appears to combine with cytokines and angiotensin-II to promote interstitial fibrosis through TGF-β (75). Exacerbating the situation, angiotensin-II levels in the blood increase with age. Levels of angiotensin-II in the circulation are regulated by the renin-angiotensin-aldosterone system and renin-angiotensin-aldosterone system inhibitors such as angiotensin-converting enzyme inhibitors or AT1 receptor antagonists reduce age-related interstitial fibrosis (75).

There are a number of mechanisms by which ROS can induce cardiomyocyte hypertrophy. In addition to promoting interstitial fibrosis, ROS and angiotensin-II also combine to induce hypertrophy through the activation of PKC, c-Jun N-terminal kinase, and ERK. Similarly, ROS potentially induces hypertrophy by potentiating TNF-α signaling to matrix metalloproteinases. ROS also promotes hypertrophy by activating the Na+/Ca2+ and Na+/H+ exchangers NCX and NHE1, respectively. These exchangers function via a Ca2+-dependent pathway. As a side effect, elevated Na+ may also explain the increased incidence of arrhythmia that is seen with advancing age (76).

Cells in the mammalian heart exit the cell cycle after birth and gradually becoming senescent. These cells accumulate in the heart where they promote organ dysfunction and decreased lifespan (77). Despite being unable to replicate, senescent cells remain metabolically active and they are marked by the so-called senescence-associated secretory phenotype (SASP). The SASP is a collection of proinflammatory proteins, proteases, and extracellular matrix proteins. Through paracrine effects, SASP proteins impair the function of adjacent cells (78). Similar to how ROS self-amplifies, SASP signaling propagates cellular senescence by inducing p53 and CDK inhibitors such as p16INK4A, p14ARF, p21CIP1, and p27 in neighboring cells (79, 80, 81). The wave of increasing numbers of senescent cells is also amplified by declines in the efficiency of mechanisms to remove them (82) (Fig. 2). Mitochondrial dysfunction may also act as a trigger for age-related inflammation. Mitochondrial DNA fragments activate TLR9 signaling, triggering the release of proinflammatory cytokines and subsequent inflammatory reactions within cardiomyocytes (83).

Clinically, pathological oxidative stress is combated via exogenous antioxidants. Vitamins A, C, and E are commonly employed and reduce ROS by increasing antioxidant enzyme activity, promoting scavenging and preventing fat oxidation, respectively (2). Other agents that can potentially reduce ROS include zinc and selenium, as well as carotinoids and flavonoids (2). Interestingly, vitamin C and selenium also appear to be important for cardiomyocyte differentiation (84, 85), suggesting that combining anti-ROS agents with cardiomyocyte proliferation methods could be beneficial in aged individuals.

Stem cells injected into the heart reverse various aging effects in the heart, including reversing age-associated ROS production. This occurs through paracrine mechanisms, whereby the injected stem cells induce GSH transferase and superoxide dismutase activity in adjacent cells (86). Research into stem cell injections has stagnated for various reasons. This is unfortunate because paracrine factors could be a “one-stop shop” as they have been shown to reduce many aging effects as well as being proregenerative (87). Exosomes are believed to be important carriers of paracrine factors and are a viable alternative to cell-based therapies (88). Similarly, bioengineering is also a viable option for the application of stem cells (89).

Elevated ROS production is not the only consequence of dysfunctional mitochondria. With aging, mitochondria also become less efficient at producing ATP. Reduced efficiency in producing ATP is due to a decrease in oxidative phosphorylation. Similarly, with age, calcium homeostasis also becomes dysregulated due to calcium mishandling and cytosolic calcium overload. This is caused in part by reduced expression of the mitochondrial calcium uniporter and MICU1. Triggers for mitochondrial dysfunction include endocrine dysfunction, systemic inflammation, nutrition, and the environment. While it is outside the scope of this review to discuss the above at length, the interested reader is directed to recent reviews on the topic (90, 91, 92). However, it is important to note that reduced ATP production, a breakdown in calcium homeostasis, endocrine dysfunction, etc are all potentially relevant for cardiac regeneration.

Genetic damage and telomere loss

Telomeres, repetitive DNA sequences found at the ends of chromosomes, play a crucial role in maintaining genome integrity (93). With each cell division, telomeres shorten and beyond a certain point DNA is damaged (94). Although cardiomyocytes are predominantly postmitotic cells, telomere shortening is still relevant in the context of cardiac aging. Telomerase deficiency, which leads to severely shortened telomeres, has been linked to age-related cardiac dysfunction and myocardial remodeling (95). Dysfunctional telomeres activate DNA-damage response proteins and in so doing, promote cellular senescence through a phenomenon known as telomere-associated DNA damage foci (78, 96, 97) (Fig. 2). Telomere-associated DNA damage foci trigger classic senescence pathways involving p21CIP and p16INK4a.

Reversing the effects of aging through partial reprogramming

Partial reprogramming is a strategy to return cells to a younger phenotype. In short, partial reprogramming utilizes transient expression of pluripotency-associated reprogramming factors, such as the Yamanaka factors Oct4, Sox2, Klf4, and c-Myc (OSKM). Transient expression of OSKM induces a youthful state while avoiding full reprogramming to an iPSC state (98, 99). Partial reprogramming has been shown to erase certain epigenetic marks of aging, effectively “rewinding” the cellular clock while preserving the cell's identity. Researchers have discovered that partial reprogramming could potentially enhance the regenerative potential of cardiomyocytes, possibly leading to improved functionality and longevity of heart tissue (100). Cardiac-specific expression of OKSM induced adult cardiomyocytes to dedifferentiate and reenter the cell cycle. The cardiomyocytes more closely resembled their fetal counterparts. Short-term OKSM expression was important as prolonged OKSM expression led to cellular reprogramming and the formation of tumors in the heart (100).

Perspectives

Despite a prolonged effort and promising results in animal studies, not a single cardiac regenerative strategy has reached the clinic. The position of this review is that this is result of a disconnect between the youth of research animals and the age of the patients that need to be treated.

Aging influences the effectiveness of current cardiac regenerative strategies

Cardiac regenerative strategies typically resolve around revascularization, resolving fibrosis or cardiomyocyte generation. To summarize the earlier discussion, these strategies are impacted by age. Aging reduces the capacity for revascularization. Thus, revascularization in an aged population via the proposed methods is likely to be less effective or require higher stimulant doses. The latter potentially runs into issues of cost and off-target effects. Similarly, aged fibroblasts respond differently to fibrotic stimuli. Injury-induced fibrotic scars are weaker in aged individuals. Moreover, interstitial fibrosis, fibrosis in the absence of injury, becomes apparent. These effects point to significant phenotypic change in fibroblasts. Considering that young and aged fibroblasts are apparently phenotypically distinct, it is not surprising that mechanisms identified as being antifibrotic in the young are not effective in the aged individual. Cardiomyocyte generation has been achieved either by cardiomyocyte proliferation or through the reprogramming of scar fibroblasts. The former has been muddied by studies reporting increased expression of one or more proliferation markers without demonstrating true cytokinesis. True cytokinesis can be achieved in cardiomyocytes in young research animals via activation of the PI3K–Akt, Wnt/β–catenin, and Hippo–YAP pathways. Nevertheless, these pathways become dysregulated with increasing age. Reprogramming of fibroblast to cardiomyocytes has not been studied in aged animals. This has been a strategy of convenience as reprogramming efficacy is essentially nonexistent in cultured adult fibroblasts (44). Recent research suggests that the focus on reprogramming in very young animals is missing important aging induced barriers. For one, as mentioned above, fibroblasts change phenotype with age. By early adulthood, cardiac fibroblasts begin to express the oxygen sensor Epas1 and that this protein is a barrier to reprogramming (44). It also appears that reprogrammed cells retain aging-related features of the original cell type (45). Thus, aging-related fibroblast dysfunction could manifest itself via the generation of dysfunctional cardiomyocytes.

The problem with ignoring the effects of aging can be highlighted by the cautionary tale of anti-inflammatories. Following cardiac injury, there is a strong inflammatory response in young research animals. In these individuals, dampening inflammatory responses via anti-inflammatories reduced injury-associated cardiac damage. Based on this research, anti-inflammatories were used in several clinical trials in an attempt to limit infarct damage. All of these trials failed to show any efficacy and the anti-inflammatories were found to have no effect on acute cardiac damage or remodeling (101). While the initial work on anti-inflammatories was carried out in young individuals, the clinical trials were performed in aged population where acute inflammatory responses are much weaker, suggesting a flawed design. When age effects are taken into account, clinical trials are more effective. Baseline expression of inflammatory proteins increases with age and trial data reporting the effects of targeting the proinflammatory protein IL-1β in a nonacute setting stated a reduced reoccurrence of adverse cardiac advents (102).

How aging research can help cardiac regeneration

As described in section 4, there is abundant research into the effects of aging. However, the findings of aging research receive scant attention in the field of cardiac regeneration. This is particularly evident with respect to mitochondrial dysfunction and elevated ROS, as well for senescence. Mitochondrial dysfunction and ROS appear to be good targets for cardiac regeneration in aged individuals. Indeed, delivery of coenzyme Q10 via the MITO-Porter system improves mitochondrial dysfunction (103). In addition, there are several other strategies targeting ROS production specifically in the mitochondria. These include MitoTEMPO, MitoQ, and SS-31/MPT-131. MitoTEMPO is a mitochondrial binding form of piperidine nitroxide. Piperidine nitroxides reduce ROS due to their ability to cycle between nitroxide, hydroxylamine, and oxoammonium forms. In animal models of heart failure, MitoTEMPO reduced ROS levels and reversed cardiac remodeling as well as improving mitochondrial function and heart contractility. MitoQ is a mitochondrial matrix-targeted ubiquinone. Once in the matrix, ubiquinone reduction to ubiquinol reduces ROS levels by reducing lipid peroxidation. Like MitoTEMPO, MitoQ improves mitochondrial function and heart contractility in injury models. SS-31 belongs to the group of Szeto-Schiller (SS) peptides, which are known to selectively bind to the inner mitochondrial membrane. The target for SS-31 is cardiolipin. By binding to cardiolipin, SS-31 prevents it from converting cytochrome c from an electron carrier into a peroxidase. As a result, SS-31 promotes the electron transport chain at the expense of ROS production. In several small and large animal models, SS-31 prevents hypertrophy, reduces fibrosis and improves cardiac function. Due to these results, several clinical trials of SS-31 in its acetate salt variant (MTP-131/bendavia/elamipretide) have been conducted. In a trial of patients with heart failure with preserved ejection fraction, MTP-131 improved cardiac function. However, in patients with ST-elevated myocardial infarction, there was no significant impact on infarct size or ventricular function (104). Beyond mitochondrial dysfunction and ROS, another attractive target for cardiac regeneration in aged individuals is senescent cells. Drugs that specifically induce senescent cells to undergo apoptosis are called senolytics (105, 106, 107). Preclinical trials suggest that senolytics can revert some of the effects of aging, such as improving vascular reactivity and cardiac function (108, 109). Beyond senolytics, there are a number of emergent technologies that specifically target senescent cells. Proteolysis-targeting chimeras degrade harmful proteins within senescent cells (110). In addition, galactose-based prodrugs exploit the heightened lysosomal activity in senescent cells, allowing for the selective release of cytotoxic agents within these cells and thereby sparing nonsenescent cells (111, 112). Finally, enhancing the immune system's natural capacity to clear senescent cells has been achieved through chimeric antigen receptor T-cell therapy (113). With the ready availability of ROS scavengers, senolytics, and the like, there are plenty of tools to investigate how to achieve cardiac regeneration in the aged population.

Combination therapies

An important way that ROS scavengers, senolytics, and the like could be helpful for cardiac regeneration in the aged population is through combination therapies. Combination therapies can be employed to target several processes in the same cell. The study of Waypa et al. suggests one possible route. This study is notable because it links cardiomyocyte proliferation with decreased mitochondrial function (114). Deletion of the mitochondrial Rieske iron–sulfur protein (Uqcrfs1) caused a decrease in mitochondrial function and metabolic shift. This shift in metabolism was associated with an increase in glucose utilization and SAM levels, while levels of alpha-ketoglutarate decreased. Concomitant with this metabolic shift, cardiomyocyte numbers were doubled (114). As mentioned earlier, dysfunctional mitochondria are a hallmark of aging. These dysfunctional mitochondria are less efficient; however, they are also super producers of ROS. In the Waypa et al. study, ROS generation was reduced in the Rieske iron–sulfur protein knockout. Taken together, this suggests that if ROS overproduction was targeted it could be possible to co-opt the reduced efficiency of aged mitochondria to drive effective cardiomyocyte proliferation.

The alternative to targeting multiple processes in a single cell would be to target several cell types. One such example would be to combine cardiomyocyte proliferation with revascularization. The expectation is that targeting several cell types would provide synergistic benefits (115). Indeed, it has been shown that human iPSC-derived endothelial cells improve the maturity and function of human iPSC-derived cardiomyocytes. When coinjected into nonhuman primates after ischemic reperfusion, significantly enhanced vasculature and improved cardiac function was observed (116). It is also important to note that while the field tends to focus on cardiomyocytes, fibroblasts, and endothelial cells, there are other cell types in the heart that potentially play a role in regeneration (117).

Conclusion

In conclusion, cardiac regenerative strategies are investigated predominantly in young adult animals. However, there are significant differences in the young adult and aged adult heart both chronically and in how they deal with injury. These differences are likely to stymie the progression of cardiac regeneration and may explain why no cardiac regenerative strategy has reached the clinic. The premise of this review is that cardiac regenerative strategies need to take aging into account. Some work has been done, notably in fibrosis and oxidative stress. Nevertheless, the impacts of many aspects of aging, such as mitochondrial dysfunction, reduced innervation, abnormal calcium homeostasis, and decreased capillary density, on cardiac regeneration are still unknown.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

Author contributions

I. A., X. W., R. E. P., V. J. D., and C. P. H. writing–review and editing; I. A., X. W., and C. P. H. writing–original draft; I. A., X. W., V. J. D., and C. P. H. conceptualization; C. P. H. supervision.
==== Refs
References

1 Gerstenblith G. Frederiksen J. Yin F.C. Fortuin N.J. Lakatta E.G. Weisfeldt M.L. Echocardiographic assessment of a normal adult aging population Circulation 56 1977 273 278 872321
2 Tracy E. Rowe G. LeBlanc A.J. Cardiac tissue remodeling in healthy aging: the road to pathology Am. J. Physiol. Cell Physiol. 319 2020 C166 C182 32432929
3 Santos F. Correia M. Nobrega-Pereira S. Bernardes de Jesus B. Age-related pathways in cardiac regeneration: a role for lncRNAs? Front. Physiol. 11 2020 583191
4 Spadaccio C. Nenna A. Rose D. Piccirillo F. Nusca A. Grigioni F. The role of angiogenesis and arteriogenesis in myocardial infarction and coronary revascularization J. Cardiovasc. Transl. Res. 15 2022 1024 1048 35357670
5 Melincovici C.S. Bosca A.B. Susman S. Marginean M. Mihu C. Istrate M. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis Rom. J. Morphol. Embryol. 59 2018 455 467 30173249
6 Song Y.Y. Liang D. Liu D.K. Lin L. Zhang L. Yang W.Q. The role of the ERK signaling pathway in promoting angiogenesis for treating ischemic diseases Front. Cell Dev. Biol. 11 2023 1164166
7 Zhang A. Fang H. Chen J. He L. Chen Y. Role of VEGF-A and LRG1 in abnormal angiogenesis associated with diabetic nephropathy Front. Physiol. 11 2020 1064 32982792
8 Moens S. Goveia J. Stapor P.C. Cantelmo A.R. Carmeliet P. The multifaceted activity of VEGF in angiogenesis - implications for therapy responses Cytokine Growth Factor Rev. 25 2014 473 482 25169850
9 Zhou Y. Zhu X. Cui H. Shi J. Yuan G. Shi S. The role of the VEGF family in coronary heart disease Front. Cardiovasc. Med. 8 2021 738325
10 Staels W. Verdonck Y. Heremans Y. Leuckx G. De Groef S. Heirman C. Vegf-A mRNA transfection as a novel approach to improve mouse and human islet graft revascularisation Diabetologia 61 2018 1804 1810 29789879
11 Anttila V. Saraste A. Knuuti J. Hedman M. Jaakkola P. Laugwitz K.L. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting Mol. Ther. 31 2023 866 874 36528793
12 Topel M.L. Hayek S.S. Ko Y.A. Sandesara P.B. Samman Tahhan A. Hesaroieh I. Sex differences in circulating progenitor cells J. Am. Heart Assoc. 6 2017 e006245
13 Xiao P. Zhang Y. Zeng Y. Yang D. Mo J. Zheng Z. Impaired angiogenesis in ageing: the central role of the extracellular matrix J. Transl Med. 21 2023 457 37434156
14 Kong P. Christia P. Frangogiannis N.G. The pathogenesis of cardiac fibrosis Cell Mol. Life Sci. 71 2014 549 574 23649149
15 Singh S. Torzewski M. Fibroblasts and their pathological functions in the fibrosis of aortic valve sclerosis and atherosclerosis Biomolecules 9 2019 472 31510085
16 Lopez B. Ravassa S. Moreno M.U. Jose G.S. Beaumont J. Gonzalez A. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches Nat. Rev. Cardiol. 18 2021 479 498 33568808
17 Maruyama K. Imanaka-Yoshida K. The pathogenesis of cardiac fibrosis: a review of recent progress Int. J. Mol. Sci. 23 2022 2617 35269759
18 Nagaraju C.K. Robinson E.L. Abdesselem M. Trenson S. Dries E. Gilbert G. Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure J. Am. Coll. Cardiol. 73 2019 2267 2282 31072570
19 Song B.W. Kim S. Kim R. Jeong S. Moon H. Kim H. Regulation of inflammation-mediated endothelial to mesenchymal transition with Echinochrome a for improving myocardial dysfunction Mar. Drugs 20 2022 756 36547903
20 Trial J. Cieslik K.A. Changes in cardiac resident fibroblast physiology and phenotype in aging Am. J. Physiol. Heart Circ. Physiol. 315 2018 H745 H755 29906228
21 Mallat Z. Philip I. Lebret M. Chatel D. Maclouf J. Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure Circulation 97 1998 1536 1539 9593557
22 Qin F. Shite J. Liang C.S. Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways Am. J. Physiol. Heart Circ. Physiol. 285 2003 H822 H832 12714335
23 Lijnen P. Papparella I. Petrov V. Semplicini A. Fagard R. Angiotensin II-stimulated collagen production in cardiac fibroblasts is mediated by reactive oxygen species J. Hypertens. 24 2006 757 766 16531806
24 Li Y. Huang T.T. Carlson E.J. Melov S. Ursell P.C. Olson J.L. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase Nat. Genet. 11 1995 376 381 7493016
25 Kwak H.B. Lee Y. Kim J.H. Van Remmen H. Richardson A.G. Lawler J.M. MnSOD overexpression reduces fibrosis and pro-apoptotic signaling in the aging mouse heart J. Gerontol. A Biol. Sci. Med. Sci. 70 2015 533 544 25016531
26 Qian L. Huang Y. Spencer C.I. Foley A. Vedantham V. Liu L. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes Nature 485 2012 593 598 22522929
27 Liu Z. Wang L. Welch J.D. Ma H. Zhou Y. Vaseghi H.R. Single-cell transcriptomics reconstructs fate conversion from fibroblast to cardiomyocyte Nature 551 2017 100 104 29072293
28 Jayawardena T.M. Finch E.A. Zhang L. Zhang H. Hodgkinson C.P. Pratt R.E. MicroRNA induced cardiac reprogramming in vivo: evidence for mature cardiac myocytes and improved cardiac function Circ. Res. 116 2015 418 424 25351576
29 Hodgkinson C.P. Kang M.H. Dal-Pra S. Mirotsou M. Dzau V.J. MicroRNAs and cardiac regeneration Circ. Res. 116 2015 1700 1711 25953925
30 Dal-Pra S. Hodgkinson C.P. Mirotsou M. Kirste I. Dzau V.J. Demethylation of H3K27 is essential for the induction of direct cardiac reprogramming by miR combo Circ. Res. 120 2017 1403 1413 28209718
31 Liu Z. Chen O. Zheng M. Wang L. Zhou Y. Yin C. Re-patterning of H3K27me3, H3K4me3 and DNA methylation during fibroblast conversion into induced cardiomyocytes Stem Cell Res. 16 2016 507 518 26957038
32 Zhou Y. Wang L. Vaseghi H.R. Liu Z. Lu R. Alimohamadi S. Bmi1 is a key epigenetic barrier to direct cardiac reprogramming Cell Stem Cell 18 2016 382 395 26942853
33 Baksh S.S. Pratt R.E. Gomez J. Dzau V.J. Hodgkinson C.P. A novel Cbx1, PurB, and Sp3 complex mediates long-term silencing of tissue- and lineage-specific genes J. Biol. Chem. 298 2022 102053
34 Mohamed T.M. Stone N.R. Berry E.C. Radzinsky E. Huang Y. Pratt K. Chemical enhancement of in vitro and in vivo direct cardiac reprogramming Circulation 135 2017 978 995 27834668
35 Ifkovits J.L. Addis R.C. Epstein J.A. Gearhart J.D. Inhibition of TGFbeta signaling increases direct conversion of fibroblasts to induced cardiomyocytes PLoS One 9 2014 e89678
36 Zhao Y. Londono P. Cao Y. Sharpe E.J. Proenza C. O'Rourke R. High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling Nat. Commun. 6 2015 8243 26354680
37 Muraoka N. Yamakawa H. Miyamoto K. Sadahiro T. Umei T. Isomi M. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures EMBO J. 33 2014 1565 1581 24920580
38 Abad M. Hashimoto H. Zhou H. Morales M.G. Chen B. Bassel-Duby R. Notch inhibition enhances cardiac reprogramming by increasing MEF2C transcriptional activity Stem Cell Rep. 8 2017 548 560
39 Zhou H. Dickson M.E. Kim M.S. Bassel-Duby R. Olson E.N. Akt1/protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes Proc. Natl. Acad. Sci. U. S. A. 112 2015 11864 11869 26354121
40 Wang L. Ma H. Huang P. Xie Y. Near D. Wang H. Down-regulation of Beclin1 promotes direct cardiac reprogramming Sci. Transl Med. 12 2020 eaay7856
41 Hodgkinson C.P. Pratt R.E. Kirste I. Dal-Pra S. Cooke J.P. Dzau V.J. Cardiomyocyte maturation requires TLR3 activated nuclear factor kappa B Stem Cells 36 2018 1198 1209 29676038
42 Baksh S.S. Hu J.B. Pratt R.E. Dzau V.J. Hodgkinson C.P. Rig1 receptor plays a critical role in cardiac reprogramming via YY1 signaling Am. J. Physiol. Cell Physiol. 324 2023 C843 C855 36847443
43 Wang X. Baksh S.S. Pratt R.E. Dzau V.J. Hodgkinson C.P. Modifying miRs for effective reprogramming of fibroblasts to cardiomyocytes Mol. Ther. Nucleic Acids 35 2024 102160
44 Sun H. Pratt R.E. Dzau V.J. Hodgkinson C.P. Neonatal and adult cardiac fibroblasts exhibit inherent differences in cardiac regenerative capacity J. Biol. Chem. 299 2023 104694
45 Mertens J. Paquola A.C.M. Ku M. Hatch E. Bohnke L. Ladjevardi S. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects Cell Stem Cell 17 2015 705 718 26456686
46 Novoyatleva T. Diehl F. van Amerongen M.J. Patra C. Ferrazzi F. Bellazzi R. TWEAK is a positive regulator of cardiomyocyte proliferation Cardiovasc. Res. 85 2010 681 690 19887380
47 Xin M. Kim Y. Sutherland L.B. Qi X. McAnally J. Schwartz R.J. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size Sci. Signal. 4 2011 ra70
48 Engel F.B. Schebesta M. Duong M.T. Lu G. Ren S. Madwed J.B. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes Genes Dev. 19 2005 1175 1187 15870258
49 Novoyatleva T. Sajjad A. Pogoryelov D. Patra C. Schermuly R.T. Engel F.B. FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14 FASEB J. 28 2014 2492 2503 24571920
50 Bersell K. Arab S. Haring B. Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury Cell 138 2009 257 270 19632177
51 Beigi F. Schmeckpeper J. Pow-Anpongkul P. Payne J.A. Zhang L. Zhang Z. C3orf58, a novel paracrine protein, stimulates cardiomyocyte cell-cycle progression through the PI3K-AKT-CDK7 pathway Circ. Res. 113 2013 372 380 23784961
52 Heallen T. Morikawa Y. Leach J. Tao G. Willerson J.T. Johnson R.L. Hippo signaling impedes adult heart regeneration Development 140 2013 4683 4690 24255096
53 Xin M. Kim Y. Sutherland L.B. Murakami M. Qi X. McAnally J. Hippo pathway effector Yap promotes cardiac regeneration Proc. Natl. Acad. Sci. U. S. A. 110 2013 13839 13844 23918388
54 Lin Z. Zhou P. von Gise A. Gu F. Ma Q. Chen J. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival Circ. Res. 116 2015 35 45 25249570
55 Tseng A.S. Engel F.B. Keating M.T. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes Chem. Biol. 13 2006 957 963 16984885
56 Liu J. Xiao Q. Xiao J. Niu C. Li Y. Zhang X. Wnt/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities Signal. Transduct. Target. Ther. 7 2022 3 34980884
57 Woo Y.J. Panlilio C.M. Cheng R.K. Liao G.P. Atluri P. Hsu V.M. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure Circulation 114 2006 I206 I213 16820573
58 Bicknell K.A. Coxon C.H. Brooks G. Forced expression of the cyclin B1-CDC2 complex induces proliferation in adult rat cardiomyocytes Biochem. J. 382 2004 411 416 15253691
59 Mohamed T.M.A. Ang Y.S. Radzinsky E. Zhou P. Huang Y. Elfenbein A. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration Cell 173 2018 104 116.12 29502971
60 Pasumarthi K.B. Nakajima H. Nakajima H.O. Soonpaa M.H. Field L.J. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice Circ. Res. 96 2005 110 118 15576649
61 Zhang P. Wong C. DePinho R.A. Harper J.W. Elledge S.J. Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development Genes Dev. 12 1998 3162 3167 9784491
62 Maddika S. Ande S.R. Wiechec E. Hansen L.L. Wesselborg S. Los M. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis J. Cell Sci. 121 2008 979 988 18354084
63 Bergmann O. Zdunek S. Felker A. Salehpour M. Alkass K. Bernard S. Dynamics of cell generation and turnover in the human heart Cell 161 2015 1566 1575 26073943
64 Senyo S.E. Steinhauser M.L. Pizzimenti C.L. Yang V.K. Cai L. Wang M. Mammalian heart renewal by pre-existing cardiomyocytes Nature 493 2013 433 436 23222518
65 Bergmann O. Clearing up the mist: cardiomyocyte renewal in human hearts Eur. Heart J. 40 2019 1037 1038 30933289
66 Lazar E. Sadek H.A. Bergmann O. Cardiomyocyte renewal in the human heart: insights from the fall-out Eur. Heart J. 38 2017 2333 2342 28810672
67 Abdellatif M. Eisenberg T. Heberle A.M. Thedieck K. Kroemer G. Sedej S. Cardiac PI3K p110alpha attenuation delays aging and extends lifespan Cell Stress 6 2022 72 75 36447531
68 Kasacka I. Piotrowska Z. Niezgoda M. Lewandowska A. Lebkowski W. Ageing-related changes in the levels of beta-catenin, CacyBP/SIP, galectin-3 and immunoproteasome subunit LMP7 in the heart of men PLoS One 15 2020 e0229462
69 Ni B. Sun M. Zhao J. Wang J. Cao Z. The role of beta-catenin in cardiac diseases Front. Pharmacol. 14 2023 1157043
70 Leach J.P. Heallen T. Zhang M. Rahmani M. Morikawa Y. Hill M.C. Hippo pathway deficiency reverses systolic heart failure after infarction Nature 550 2017 260 264 28976966
71 Schriner S.E. Linford N.J. Martin G.M. Treuting P. Ogburn C.E. Emond M. Extension of murine life span by overexpression of catalase targeted to mitochondria Science 308 2005 1909 1911 15879174
72 Pagan L.U. Gomes M.J. Gatto M. Mota G.A.F. Okoshi K. Okoshi M.P. The role of oxidative stress in the aging heart Antioxidants (Basel) 11 2022 336 35204217
73 Cilleros-Holgado P. Gomez-Fernandez D. Pinero-Perez R. Reche-Lopez D. Alvarez-Cordoba M. Munuera-Cabeza M. mtUPR modulation as a therapeutic target for primary and secondary mitochondrial diseases Int. J. Mol. Sci. 24 2023 1482 36674998
74 Song M. Franco A. Fleischer J.A. Zhang L. Dorn G.W. 2nd Abrogating mitochondrial dynamics in mouse hearts accelerates mitochondrial senescence Cell Metab. 26 2017 872 883.e5 29107503
75 Osorio J.M. Espinoza-Perez C. Rimassa-Tare C. Machuca V. Bustos J.O. Vallejos M. Senescent cardiac fibroblasts: a key role in cardiac fibrosis Biochim. Biophys. Acta Mol. Basis Dis. 1869 2023 166642
76 Mongirdiene A. Skrodenis L. Varoneckaite L. Mierkyte G. Gerulis J. Reactive oxygen species induced pathways in heart failure pathogenesis and potential therapeutic strategies Biomedicines 10 2022 602 35327404
77 Baker D.J. Childs B.G. Durik M. Wijers M.E. Sieben C.J. Zhong J. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan Nature 530 2016 184 189 26840489
78 Anderson R. Lagnado A. Maggiorani D. Walaszczyk A. Dookun E. Chapman J. Length-independent telomere damage drives post-mitotic cardiomyocyte senescence EMBO J. 38 2019 e100492
79 Salama R. Sadaie M. Hoare M. Narita M. Cellular senescence and its effector programs Genes Dev. 28 2014 99 114 24449267
80 Gu J. Wang S. Guo H. Tan Y. Liang Y. Feng A. Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis Cell Death Dis. 9 2018 82 29362483
81 Chicas A. Wang X. Zhang C. McCurrach M. Zhao Z. Mert O. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence Cancer Cell 17 2010 376 387 20385362
82 Munoz-Espin D. Serrano M. Cellular senescence: from physiology to pathology Nat. Rev. Mol. Cell Biol. 15 2014 482 496 24954210
83 Oka T. Hikoso S. Yamaguchi O. Taneike M. Takeda T. Tamai T. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure Nature 485 2012 251 255 Erratum in: Nature. 2012 Oct 11;490(7419):292 22535248
84 Wang X. Hodgkinson C.P. Lu K. Payne A.J. Pratt R.E. Dzau V.J. Selenium augments microRNA directed reprogramming of fibroblasts to cardiomyocytes via nanog Sci. Rep. 6 2016 23017
85 Hsueh Y.C. Pratt R.E. Dzau V.J. Hodgkinson C.P. Novel method of differentiating human induced pluripotent stem cells to mature cardiomyocytes via Sfrp2 Sci. Rep. 13 2023 3920 36894665
86 Valle-Prieto A. Conget P.A. Human mesenchymal stem cells efficiently manage oxidative stress Stem Cells Dev. 19 2010 1885 1893 20380515
87 Hodgkinson C.P. Bareja A. Gomez J.A. Dzau V.J. Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology Circ. Res. 118 2016 95 107 26837742
88 Sun S.J. Wei R. Li F. Liao S.Y. Tse H.F. Mesenchymal stromal cell-derived exosomes in cardiac regeneration and repair Stem Cell Rep. 16 2021 1662 1673
89 Alhejailan R.S. Garoffolo G. Raveendran V.V. Pesce M. Cells and materials for cardiac repair and regeneration J. Clin. Med. 12 2023 3398 37240504
90 Lima T. Li T.Y. Mottis A. Auwerx J. Pleiotropic effects of mitochondria in aging Nat. Aging 2 2022 199 213 37118378
91 Panel M. Ghaleh B. Morin D. Mitochondria and aging: a role for the mitochondrial transition pore? Aging Cell 17 2018 e12793
92 Duarte-Hospital C. Tete A. Brial F. Benoit L. Koual M. Tomkiewicz C. Mitochondrial dysfunction as a hallmark of environmental injury Cells 11 2021 110 35011671
93 Turner K.J. Vasu V. Griffin D.K. Telomere biology and human phenotype Cells 8 2019 73 30669451
94 Griffith J.D. Comeau L. Rosenfield S. Stansel R.M. Bianchi A. Moss H. Mammalian telomeres end in a large duplex loop Cell 97 1999 503 514 10338214
95 Wong L.S. Oeseburg H. de Boer R.A. van Gilst W.H. van Veldhuisen D.J. van der Harst P. Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing Cardiovasc. Res. 81 2009 244 252 19047341
96 Fumagalli M. Rossiello F. Clerici M. Barozzi S. Cittaro D. Kaplunov J.M. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation Nat. Cell Biol. 14 2012 355 365 22426077
97 Hewitt G. Jurk D. Marques F.D. Correia-Melo C. Hardy T. Gackowska A. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence Nat. Commun. 3 2012 708 22426229
98 Yucel A.D. Gladyshev V.N. The long and winding road of reprogramming-induced rejuvenation Nat. Commun. 15 2024 1941 38431638
99 Lu Y.C. Brommer B. Tian X. Krishnan A. Meer M. Wang C. Reprogramming to recover youthful epigenetic information and restore vision Nature 588 2020 124 129 33268865
100 Chen Y.P. Lüttmann F.F. Schoger E. Schöler H.R. Zelarayán L.C. Kim K.P. Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice Science 373 2021 1537 1540 34554778
101 Seropian I.M. Toldo S. Van Tassell B.W. Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction J. Am. Coll. Cardiol. 63 2014 1593 1603 24530674
102 Ferrucci L. Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty Nat. Rev. Cardiol. 15 2018 505 522 30065258
103 Hibino M. Maeki M. Tokeshi M. Ishitsuka Y. Harashima H. Yamada Y. A system that delivers an antioxidant to mitochondria for the treatment of drug-induced liver injury Sci. Rep. 13 2023 6961 37164988
104 Peoples J.N. Saraf A. Ghazal N. Pham T.T. Kwong J.Q. Mitochondrial dysfunction and oxidative stress in heart disease Exp. Mol. Med. 51 2019 1 13
105 Farr J.N. Xu M. Weivoda M.M. Monroe D.G. Fraser D.G. Onken J.L. Targeting cellular senescence prevents age-related bone loss in mice Nat. Med. 23 2017 1072 1079 28825716
106 Lewis-McDougall F.C. Ruchaya P.J. Domenjo-Vila E. Shin Teoh T. Prata L. Cottle B.J. Aged-senescent cells contribute to impaired heart regeneration Aging Cell 18 2019 e12931
107 Wissler Gerdes E.O. Zhu Y. Tchkonia T. Kirkland J.L. Discovery, development, and future application of senolytics: theories and predictions FEBS J. 287 2020 2418 2427 32112672
108 Roos C.M. Zhang B. Palmer A.K. Ogrodnik M.B. Pirtskhalava T. Thalji N.M. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice Aging Cell 15 2016 973 977 26864908
109 Zhu Y. Tchkonia T. Pirtskhalava T. Gower A.C. Ding H. Giorgadze N. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs Aging Cell 14 2015 644 658 25754370
110 Burslem G.M. Crews C.M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery Cell 181 2020 102 114 31955850
111 Gonzalez-Gualda E. Paez-Ribes M. Lozano-Torres B. Macias D. Wilson J.R. 3rd Gonzalez-Lopez C. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity Aging Cell 19 2020 e13142
112 Wakita M. Takahashi A. Sano O. Loo T.M. Imai Y. Narukawa M. A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells Nat. Commun. 11 2020 1935 32321921
113 Amor C. Feucht J. Leibold J. Ho Y.J. Zhu C. Alonso-Curbelo D. Senolytic CAR T cells reverse senescence-associated pathologies Nature 583 2020 127 132 32555459
114 Waypa G.B. Smith K.A. Mungai P.T. Dudley V.J. Helmin K.A. Singer B.D. Mitochondria regulate proliferation in adult cardiac myocytes J Clin Invest. 134 2024 e165482
115 Wang J. An M. Haubner B.J. Penninger J.M. Cardiac regeneration: options for repairing the injured heart Front. Cardiovasc. Med. 9 2022 981982
116 Cheng Y.C. Hsieh M.L. Lin C.J. Chang C.M.C. Huang C.Y. Puntney R. Combined treatment of human induced pluripotent stem cell-derived cardiomyocytes and endothelial cells regenerate the infarcted heart in mice and non-human primates Circulation 148 2023 1395 1409 37732466
117 Bei Y. Zhou Q. Sun Q. Xiao J. Telocytes in cardiac regeneration and repair Semin. Cell Dev. Biol. 55 2016 14 21 26826525
